Month: April 2024

TORONTO and NEW YORK, April 23, 2024 (GLOBE NEWSWIRE) — illumin Holdings Inc. (TSX: ILLM) (“illumin” or the “Company”), a journey advertising technology company that empowers marketers to make smarter decisions about communicating with online consumers, today announced the relaunch of illumin Elect with a direct, in platform integration to L2’s comprehensive voter database. This new integration dramatically reduces the turnaround time for building and utilizing custom audiences for political campaigns, revolutionizing the landscape of political campaign marketing. illumin Elect maximizes the capabilities of its existing connected journey advertising platform, facilitating efficient customization of political advertisements. Marketers gain access to integrated social media campaigns across Facebook and Instagram, enabling tailored...

VANCOUVER, British Columbia, April 23, 2024 (GLOBE NEWSWIRE) — Metasphere Labs Inc. (formerly Looking Glass Labs Ltd., “Metasphere” or the “Company“) (Cboe Canada: LABZ) (OTC: LABZF) (FRA: H1N) is proud to announce an initiative to develop a pioneering bitcoin-based identity system, leveraging the “Spaces Protocol” to enable decentralized digital identities. This system uses Bitcoin’s infrastructure to offer a scalable and permissionless identity framework, enhancing online authenticity and security. Combatting AI-Driven Spam and Disinformation In response to the growing challenge of AI-driven spam and disinformation, Metasphere’s new system aims to authenticate real human and multimedia interactions. This initiative is a key step toward ensuring the integrity of online content and...

– ARCALYST® (rilonacept) Q1 2024 net product revenue of $78.9 million, representing 85% year-over-year growth –– ARCALYST 2024 expected net product revenue increased to $370 – $390 million –– Abiprubart Phase 2b trial in Sjögren’s Disease planned to initiate in 2H 2024 –– Current operating plan expected to remain cash flow positive on an annual basis – – Conference call and webcast scheduled for 8:30 am ET today – HAMILTON, Bermuda, April 23, 2024 (GLOBE NEWSWIRE) — Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (Kiniksa), a commercial-stage biopharmaceutical company with a pipeline of immune-modulating assets designed to target a spectrum of cardiovascular and autoimmune diseases, today reported first quarter 2024 financial results and recent portfolio execution. “One of the drivers of strong ARCALYST growth is an expanding...

Figure 1MD-RTEC Option for LithiumFigure 2Wookie ProjectMONTREAL, April 23, 2024 (GLOBE NEWSWIRE) — Midland Exploration Inc. (“Midland”) (TSX-V: MD), is pleased to announce the execution of an amended option agreement on April 22, 2024 (the “Option Agreement”) with Rio Tinto Exploration Canada Inc. (“RTEC”) and the addition of the Wookie project to the option agreement signed with RTEC in June 2023 (see press release by Midland dated June 14, 2023). The Wookie project is located in Eeyou Istchee James Bay area. The amended option agreement now consists of eleven (11) projects totalling 2,208 claims covering a surface of about 1,139 square kilometres. These projects include Galinée, Corvette, Mythril East, Chisaayuu, Moria, Shire, Komo, Warp, Sulu, Picard and Wookie (the “Properties”). Highlights:Addition of...

Results of Phase 1b/2 in China reinforce global clinical development rationale and plans for LSTA1 BASKING RIDGE, N.J. and JINAN, China, April 23, 2024 (GLOBE NEWSWIRE) —  Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, and Qilu Pharmaceutical Co., Ltd. (“Qilu”), one of the leading vertically integrated pharmaceutical companies in China that develops, manufactures, and distributes both finished products and active pharmaceutical ingredients, announced that the first patient has been treated in Qilu’s Phase 2 trial in China evaluating LSTA1 (also known as “CEND-1”), Lisata’s lead product candidate, in combination with standard-of-care (“SoC”) chemotherapy as a first-line...

TROY, Mich., April 23, 2024 (GLOBE NEWSWIRE) — KellyOCG, the outsourcing and consulting group of Kelly (Nasdaq: KELYA, KELYB), has earned recognition as a Partner-level supplier for 2023 in the John Deere Achieving Excellence Program. The Partner-level status is Deere & Company’s highest supplier rating. KellyOCG is a supplier of Managed Service Provider (MSP) and Recruitment Process Outsourcing (RPO) solutions to John Deere’s operation in the U.S. and Canada. It was selected for the honor in recognition of its dedication to providing products and service of outstanding quality as well as its commitment to continuous improvement. In addition, KellyOCG has earned recognition for 2023 in the John Deere Cost Reduction Opportunities Process (JD CROP). JD CROP, a supplier suggestion process, is part of Deere & Company’s Achieving...

TORONTO, April 23, 2024 (GLOBE NEWSWIRE) — BULGOLD Inc. (TSXV: ZLTO) (the “Company” or “BULGOLD”) is pleased to announce that it has filed its audited condensed interim financial statements and MD&A for the fourth quarter and year ended December 31, 2023. During the three months ended December 31, 2023, the Company incurred a net loss of $264,578 ($0.01 per share). For the year ending December 31, 2023, the company incurred a net loss of $1,873,160 ($0.08 per share), including a non-cash expense of $734,269 being the cost of listing (the cost of listing relates to the recently completed acquisition of assets in Bulgaria). Other expenses incurred, primarily related to professional fees for the completion of the acquisition. On December 31, 2023, the company had cash (and cash equivalents) of $2,015,716 (net working capital...